Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-peptide for Insulin-induced Hypoglycemia in T1D
NCT06470295Phase 1Recruiting
- Sponsor
- University of Cincinnati
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of C-peptide in type 1 diabetes mellitus (T1D) and hypoglycemia (4 arms), sponsored by University of Cincinnati. Primary endpoint: Glucagon levels up to 2.5 hours. Started Jun 2024; status: recruiting.
02
Drugs
C-peptide
03
Conditions
type 1 diabetes mellitus (T1D)hypoglycemia
Beyond the preview
Go deeper on NCT06470295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470295.